Tags

Type your tag names separated by a space and hit enter

The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy.
Pharmacol Biochem Behav. 2007 Aug-Sep; 87(3):306-14.PB

Abstract

Dopamine (DA) replacement therapy with l-DOPA remains the standard pharmacotherapy for Parkinson's disease (PD). Unfortunately, chronic l-DOPA treatment is accompanied by development of motor fluctuations and l-DOPA-induced dyskinesia (LID). While serotonin (5-HT)(1A) agonists acutely reduce these complications, their prophylactic and long-term effects are not well-delineated. To test this, male Sprague-Dawley rats received unilateral 6-hydroxydopamine (6-OHDA) lesions. In experiment 1, l-DOPA-primed rats were pre-treated with Vehicle (0.9% NaCl), various doses of the partial 5-HT(1A) agonist, buspirone (0.25, 1.0 or 2.5 mg/kg, ip) or buspirone (2.5 mg/kg, ip)+the 5-HT(1A) antagonist, WAY100635 (0.5 mg/kg, ip) 5 min prior to l-DOPA (12 mg/kg+15 mg/kg benserazide, ip). Rats were tested for LID using the abnormal involuntary movements (AIMs) scale and motor performance using the forepaw adjusting steps test (FAS). In experiment 2, l-DOPA-naïve rats received co-administration of l-DOPA+buspirone (1.0 or 2.5 mg/kg, ip) for 2 weeks. AIMs and FAS were measured throughout. In l-DOPA-primed rats, buspirone dose-dependently reduced LID and improved l-DOPA-related motor performance due to action at the 5-HT(1A) receptor. In l-DOPA-naïve rats, buspirone delayed LID development while improving l-DOPA's anti-parkinsonian efficacy indicating the potential long-term benefits of 5-HT(1A) agonists for reduction of l-DOPA-related side effects.

Authors+Show Affiliations

Behavioral Neuroscience Program, Department of Psychology, State University of New York at Binghamton, 4400 Vestal Parkway East, Binghamton, NY 13902-6000, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17553556

Citation

Eskow, Karen L., et al. "The Partial 5-HT(1A) Agonist Buspirone Reduces the Expression and Development of l-DOPA-induced Dyskinesia in Rats and Improves l-DOPA Efficacy." Pharmacology, Biochemistry, and Behavior, vol. 87, no. 3, 2007, pp. 306-14.
Eskow KL, Gupta V, Alam S, et al. The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy. Pharmacol Biochem Behav. 2007;87(3):306-14.
Eskow, K. L., Gupta, V., Alam, S., Park, J. Y., & Bishop, C. (2007). The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy. Pharmacology, Biochemistry, and Behavior, 87(3), 306-14.
Eskow KL, et al. The Partial 5-HT(1A) Agonist Buspirone Reduces the Expression and Development of l-DOPA-induced Dyskinesia in Rats and Improves l-DOPA Efficacy. Pharmacol Biochem Behav. 2007 Aug-Sep;87(3):306-14. PubMed PMID: 17553556.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy. AU - Eskow,Karen L, AU - Gupta,Vikas, AU - Alam,Salmahn, AU - Park,John Y, AU - Bishop,Christopher, Y1 - 2007/05/13/ PY - 2007/03/02/received PY - 2007/04/26/revised PY - 2007/05/03/accepted PY - 2007/6/8/pubmed PY - 2007/10/13/medline PY - 2007/6/8/entrez SP - 306 EP - 14 JF - Pharmacology, biochemistry, and behavior JO - Pharmacol Biochem Behav VL - 87 IS - 3 N2 - Dopamine (DA) replacement therapy with l-DOPA remains the standard pharmacotherapy for Parkinson's disease (PD). Unfortunately, chronic l-DOPA treatment is accompanied by development of motor fluctuations and l-DOPA-induced dyskinesia (LID). While serotonin (5-HT)(1A) agonists acutely reduce these complications, their prophylactic and long-term effects are not well-delineated. To test this, male Sprague-Dawley rats received unilateral 6-hydroxydopamine (6-OHDA) lesions. In experiment 1, l-DOPA-primed rats were pre-treated with Vehicle (0.9% NaCl), various doses of the partial 5-HT(1A) agonist, buspirone (0.25, 1.0 or 2.5 mg/kg, ip) or buspirone (2.5 mg/kg, ip)+the 5-HT(1A) antagonist, WAY100635 (0.5 mg/kg, ip) 5 min prior to l-DOPA (12 mg/kg+15 mg/kg benserazide, ip). Rats were tested for LID using the abnormal involuntary movements (AIMs) scale and motor performance using the forepaw adjusting steps test (FAS). In experiment 2, l-DOPA-naïve rats received co-administration of l-DOPA+buspirone (1.0 or 2.5 mg/kg, ip) for 2 weeks. AIMs and FAS were measured throughout. In l-DOPA-primed rats, buspirone dose-dependently reduced LID and improved l-DOPA-related motor performance due to action at the 5-HT(1A) receptor. In l-DOPA-naïve rats, buspirone delayed LID development while improving l-DOPA's anti-parkinsonian efficacy indicating the potential long-term benefits of 5-HT(1A) agonists for reduction of l-DOPA-related side effects. SN - 0091-3057 UR - https://www.unboundmedicine.com/medline/citation/17553556/The_partial_5_HT_1A__agonist_buspirone_reduces_the_expression_and_development_of_l_DOPA_induced_dyskinesia_in_rats_and_improves_l_DOPA_efficacy_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0091-3057(07)00149-9 DB - PRIME DP - Unbound Medicine ER -